Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T11822
|
||||
Former ID |
TTDS00072
|
||||
Target Name |
Retinoic acid receptor
|
||||
Target Type |
Successful
|
||||
Disease | Acne vulgaris [ICD9: 706.1; ICD10: L70.0] | ||||
Acute promyelocytic leukemia [ICD9: 205; ICD10: C92.4] | |||||
Breast cancer [ICD9: 174, 175; ICD10: C50] | |||||
Cancer [ICD9: 140-229; ICD10: C00-C96] | |||||
Glioma [ICD9: 191; ICD10: C71] | |||||
Hepatocellular carcinoma [ICD9: 155; ICD10: C22.0] | |||||
Macular degeneration [ICD9: 362.5; ICD10: H35.3] | |||||
Night blindness [ICD9: 368.6; ICD10: H53.6] | |||||
Psoriasis [ICD9: 696; ICD10: L40] | |||||
Rosacea [ICD10: L71] | |||||
BioChemical Class |
Zinc-finger
|
||||
Target Validation |
T11822
|
||||
Drugs and Mode of Action | |||||
Drug(s) | Adapalene | Drug Info | Approved | Acne vulgaris | [536911], [540832] |
Isotretinoin | Drug Info | Approved | Acne vulgaris | [536361], [542589] | |
Tretinoin | Drug Info | Approved | Acne vulgaris | [536361], [539710] | |
Vitamin A | Drug Info | Approved | Night blindness | [537623], [540652] | |
13-cis-retinoic acid, UCSD | Drug Info | Phase 3 | Glioma | [525348] | |
Fenretinide | Drug Info | Phase 3 | Macular degeneration | [521449] | |
Peretinoin | Drug Info | Phase 3 | Hepatocellular carcinoma | [523972] | |
Velac Gel | Drug Info | Phase 3 | Acne vulgaris | [525348] | |
Amsilarotene | Drug Info | Phase 2 | Cancer | [522335] | |
Tretinoin | Drug Info | Phase 2 | Acute promyelocytic leukemia | [525348], [539710] | |
LAS-41001 | Drug Info | Discontinued in Preregistration | Rosacea | [548717] | |
IRX-4310 | Drug Info | Discontinued in Phase 3 | Psoriasis | [546671] | |
BMY-30123 | Drug Info | Discontinued in Phase 2 | Acne vulgaris | [545453] | |
LG-1550 | Drug Info | Discontinued in Phase 2 | Cancer | [539785], [546388] | |
MX-781 | Drug Info | Terminated | Breast cancer | [546931] | |
Modulator | 13-cis-retinoic acid, UCSD | Drug Info | [525851], [551871] | ||
BMY-30123 | Drug Info | [526777], [551871] | |||
Fenretinide | Drug Info | [550397] | |||
LAS-41001 | Drug Info | [548718] | |||
LG-1550 | Drug Info | [550887] | |||
MX-781 | Drug Info | [527172] | |||
Peretinoin | Drug Info | [532310] | |||
Binder | Adapalene | Drug Info | [535694], [536877] | ||
Tretinoin | Drug Info | [535273] | |||
Vitamin A | Drug Info | [537623] | |||
Antagonist | Amsilarotene | Drug Info | [526402] | ||
IRX-4310 | Drug Info | [527142] | |||
Agonist | Isotretinoin | Drug Info | [535834] | ||
Inhibitor | Velac Gel | Drug Info | [525349] | ||
References | |||||
Ref 521449 | ClinicalTrials.gov (NCT00003075) Fenretinide in Treating Patients With Cervical Neoplasia. U.S. National Institutes of Health. | ||||
Ref 522335 | ClinicalTrials.gov (NCT00687596) Study of TAC-101 as Second Line Treatment in Patients With Advanced Hepatocellular Carcinoma Who Received Sorafenib as First Line Therapy. U.S. National Institutes ofHealth. | ||||
Ref 523972 | ClinicalTrials.gov (NCT01640808) Study of Peretinoin for Suppressing Recurrence of HCV-positive HCC. U.S. National Institutes of Health. | ||||
Ref 525348 | Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell. 1991 Aug 23;66(4):663-74. | ||||
Ref 536361 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. Epub 2007 Feb 20. | ||||
Ref 536911 | Topical retinoids in acne vulgaris: update on efficacy and safety. Am J Clin Dermatol. 2008;9(6):369-81. doi: 10.2165/0128071-200809060-00003. | ||||
Ref 539710 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2644). | ||||
Ref 539785 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2740). | ||||
Ref 540652 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4053). | ||||
Ref 540832 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5429). | ||||
Ref 542589 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7600). | ||||
Ref 545453 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003321) | ||||
Ref 546388 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007857) | ||||
Ref 546671 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009573) | ||||
Ref 525349 | Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor, PML. Cell. 1991 Aug 23;66(4):663-74. | ||||
Ref 525851 | 13-cis retinoic acid exerts its specific activity on human sebocytes through selective intracellular isomerization to all-trans retinoic acid and binding to retinoid acid receptors. J Invest Dermatol. 2000 Aug;115(2):321-7. | ||||
Ref 526402 | Initial clinical trial of oral TAC-101, a novel retinoic acid receptor-alpha selective retinoid, in patients with advanced cancer. J Clin Oncol. 2002 Aug 15;20(16):3522-32. | ||||
Ref 526777 | The pharmacology of a novel topical retinoid, BMY 30123: comparison with tretinoin. J Pharm Pharmacol. 1992 May;44(5):379-86. | ||||
Ref 527142 | An antagonist of retinoic acid receptors more effectively inhibits growth of human prostate cancer cells than normal prostate epithelium. Br J Cancer. 2004 Aug 2;91(3):580-8. | ||||
Ref 527172 | The retinoid antagonist MX781 induces clusterin expression in prostate cancer cells via heat shock factor-1 and activator protein-1 transcription factors. Cancer Res. 2004 Aug 15;64(16):5905-12. | ||||
Ref 532310 | Peretinoin, an acyclic retinoid, improves the hepatic gene signature of chronic hepatitis C following curative therapy of hepatocellular carcinoma. BMC Cancer. 2013 Apr 15;13:191. | ||||
Ref 535273 | Retinoids--which dermatological indications will benefit in the near future? Skin Pharmacol Appl Skin Physiol. 2001 Sep-Oct;14(5):303-15. | ||||
Ref 535694 | Topical treatment in acne: current status and future aspects. Dermatology. 2003;206(1):29-36. | ||||
Ref 535834 | Retinoid agonist isotretinoin ameliorates obstructive renal injury. J Urol. 2003 Oct;170(4 Pt 1):1398-402. | ||||
Ref 536877 | A review of adapalene in the treatment of acne vulgaris. J Adolesc Health. 2008 Nov;43(5):421-4. | ||||
Ref 548718 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027956) |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.